Insider Trading April 29, 2026 09:28 PM

Slide Insurance CRO Matthew Larson Executes Multi-Day Stock Sale Totaling Over $1.1 Million

Transactions were conducted under a pre-arranged 10b5-1 trading plan following strong Q1 earnings performance.

By Sofia Navarro SLDE
Slide Insurance CRO Matthew Larson Executes Multi-Day Stock Sale Totaling Over $1.1 Million
SLDE

Matthew Larson, the Chief Risk Officer of Slide Insurance Holdings, Inc. (NASDAQ: SLDE), completed a series of stock transactions in late April that resulted in the sale of 56,002 shares of common stock for approximately $1,107,097. These sales, which occurred between April 27 and April 29, 2026, were executed as part of a 10b5-1 trading plan that was originally established on December 4, 2025. The transactions involved the exercise of fully vested stock options followed by immediate sales.

Key Points

  • Slide Insurance reported a significant earnings beat in Q1 2026, with an EPS of $1.02 against an expected $0.67.
  • CRO Matthew Larson sold over $1.1 million in stock via a pre-established 10b5-1 plan.
  • The company maintains a strong financial health score and is currently identified as potentially undervalued.

Matthew Larson, serving as the Chief Risk Officer for Slide Insurance Holdings, Inc. (NASDAQ: SLDE), has finalized a series of equity transactions totaling more than $1.1 million. According to recent filings, the executive sold 56,002 shares of common stock during a window in late April 2026, specifically spanning from April 27 to April 29.

The liquidation of these shares was conducted under the framework of a 10b5-1 trading plan. This specific plan had been adopted by Mr. Larson on December 4, 2025, to govern the timing and execution of such trades. The total proceeds generated from these transactions are estimated at approximately $1,107,097.


Transaction Breakdown

The series of sales occurred in three distinct phases involving both the exercise of options and subsequent market sales:

  • April 27 Transactions: Mr. Larson first exercised options to acquire 1,250 shares of common stock at an exercise price of $0.79 per share. These options were noted as being fully vested and exercisable. He immediately sold these 1,250 shares at a weighted average price of $18.77 per share, with individual prices in this block ranging from $18.43 to $19.00, totaling roughly $23,462. Later that same day, he exercised an additional 10,000 shares at the same $0.79 exercise price. These were also fully vested and immediately sold at a weighted average of $18.77 per share (ranging from $18.43 to $19.00), resulting in approximately $187,700.

  • April 29 Transactions: Two days later, Mr. Larson exercised options for 44,752 shares of common stock at an exercise price of $0.79 per share. These shares were also fully vested and exercisable. This final block was sold at a weighted average price of $20.02 per share, with individual sale prices ranging between $20.00 and $20.17, amounting to approximately $895,944.

Company Financial Context

The stock sales took place while SLDE was trading at $18.41. Despite the insider selling, analysis suggests the company's stock may be undervalued relative to its Fair Value, placing it on a list of most undervalued stocks. Slide Insurance Holdings, Inc., which holds a market valuation of $2.16 billion, has maintained an "EXCELLENT" financial health score of 3.88.

This insider activity follows a period of significant financial strength for the company. In its reported first-quarter earnings for 2026, Slide Insurance exceeded analyst expectations by a wide margin. The firm reported earnings per share (EPS) of $1.02, which surpassed the anticipated $0.67 by 52.24%. Additionally, the company recorded revenue of $389.3 million during this period. These results have highlighted the company's operational execution and have drawn significant attention from the financial community and market observers.


Key Analysis Points

  • Strong Operational Execution: The company has demonstrated a capacity to beat earnings projections, as evidenced by the 52.24% surprise in EPS during Q1 2026. This reflects robust performance within the insurance sector.
  • Valuation Divergence: There is a notable distinction between recent insider selling and current valuation metrics, with data suggesting the stock remains undervalued relative to its calculated Fair Value.
  • Structured Liquidation: The use of a 10b5-1 plan indicates that these sales were scheduled in advance, rather than being spontaneous reactions to immediate market shifts.

Market Risks and Uncertainties

  • Valuation Sensitivity: While current analysis suggests the stock is undervalued, all equity investments carry inherent risks regarding whether market prices will eventually align with perceived fair value.
  • Earnings Sustainability: The recent surge in EPS and revenue presents a high benchmark for future quarters; maintaining this level of outperformance represents a continuous operational challenge.

Risks

  • Potential difficulty in sustaining the high growth rates seen in the recent Q1 earnings surprise.
  • Market volatility affecting whether the stock reaches its projected Fair Value.

More from Insider Trading

Marcus & Millichap Director Executes Substantial Common Stock Purchase May 4, 2026 Patterson-UTI CEO Executes Multi-Million Dollar Stock Sale Amidst Year-to-Date Surge May 4, 2026 Snowflake Director Michael Speiser Executes $7.18 Million in Stock Sales May 4, 2026 Edwards Lifesciences Executive Executes Stock Transactions Amid Recent Financial Growth May 4, 2026 Entrada Therapeutics President and COO Executes Stock Sale via Rule 10b5-1 Plan May 4, 2026